propafen 300 mg/1 tableta film tableta
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - пропафенона - film tableta - 300 mg/1 tableta - 1 film tableta sadrži: 300 mg propafenonhidrohlorida
propafen 150 mg/1 tableta film tableta
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - пропафенона - film tableta - 150 mg/1 tableta - 1 film tableta sadrži: 150 mg propafenonhidrohlorida
propafenon alkaloid 150 mg/1 tableta film tableta
alkaloid d.o.o. sarajevo - пропафенона - film tableta - 150 mg/1 tableta - 1 film tableta sadrži : 150 mg propafenonhidrohlorid
propafenon farmavita 150 mg/1 tableta filmom obložena tableta
farmavita d.o.o. sarajevo - пропафенона - filmom obložena tableta - 150 mg/1 tableta - 1 filmom obložena tableta sadrži: 150 mg propafenon u obliku propafenonhidrohlorida
aritmon 150 mg/1 tableta film tableta
zada pharmaceuticals d.o.o. - пропафенона - film tableta - 150 mg/1 tableta - 1 tableta sadrži: 150 mg propafenonhidrohlorid
aritmon 300 mg/1 tableta film tableta
zada pharmaceuticals d.o.o. - пропафенона - film tableta - 300 mg/1 tableta - 1 tableta sadrži: 300 mg propafenonhidrohlorid
aritmon 150 mg/1 tableta film tableta
zada pharmaceuticals d.o.o. - пропафенона - film tableta - 150 mg/1 tableta - 1 tableta sadrži: 150 mg propafenonhidrohlorid
propafen 300 mg/1 tableta film tableta
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - пропафенона - film tableta - 300 mg/1 tableta - 1 film tableta sadrži: 300 mg propafenon hidrohlorida
propafen 150 mg/1 tableta film tableta
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - пропафенона - film tableta - 150 mg/1 tableta - 1 film tableta sadrži: 150 mg propafenon hidrohlorida
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doksorubicin hidroklorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastična sredstva - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).